Latest publication on ET-traps shows the potential to prevent morbidity and mortality in preeclampsia. Currently, available treatments in preeclampsia target maternal hypertension and seizures but the cure is delivery of the dysfunctional placenta and baby, often prematurely.
By reducing elevated ET-1 levels in the body to non-disease levels, ET-traps would help reduce hypertension, proteinuria, ER stress.
Published in Drug Discovery Today, September 2023 Read more
ET-traps have been found to be a potential therapeutic for ameliorating different pathologies related to elevated ET-1 levels, such as disruptions in the heart and kidney functions. Hence, the ET-traps could effectively tackle serious health conditions associated with disruptions in the endothelin system. This paper discusses the potential application of ET-traps as a therapeutic for use in human complications of the heart and kidneys. Published , January 2023 Read more
This study demonstrated the selected ET-traps potently and significantly bind to ET-1
The research paper has been published in the World Journal of Diabetes, June 2022 Read more
Latest publication on the potential use of ET-traps for COVID-19. It should be noted that we have already established proof-of-concept both at the in vitro and in vivo levels in the diabetes disease space. And diabetics are at higher risk of a serious COVID-19 infection. This paper also fully discusses the merits of ET-traps as a potential therapeutic for the COVID-19 pandemic.
This article has been published in the Medicine in Drug Discovery, June 2020 Read more
New academic paper has been published in "Drug Discovery Today" entitled "ET-traps offer a potential therapeutic tool for use in different autoimmune diseases", April 2020 Read more.
New academic paper has been published in "Drug Discovery Today" entitled "Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?", September 2019. Read more
New academic paper has been published in the "Journal of Diabetes & Metabolic Disorders " entitled " In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes".
Read More →Mar14, 2019
Another publication pertaining to ET-traps was published in the "Journal of Diabetes & Metabolic Disorders " entitled "Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes".
Read More →Oct1, 2018